Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
Liang Deng,Stewart Shuman,Jedd Wolchok,Taha Merghoub,Weiyi Wang,Peihong Dai,Ning Yang
申请号：
US16673475
公开号：
US10765711B2
申请日:
2019.11.04
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK−；) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.
